← All trials
NCT06912087
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2025
- Primary completion
- Jun 5, 2027
- Completion date
- Jun 5, 2027
- First posted
- Apr 4, 2025
- Last posted
- Oct 16, 2025
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ChicagoLead sponsor
- ExelixisCollaborator
- University of ChicagoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.